Enfusion, Inc. (ENFN)
Total Valuation
Enfusion has a market cap or net worth of $817.83 million. The enterprise value is $797.66 million.
Market Cap | 817.83M |
Enterprise Value | 797.66M |
Important Dates
The last earnings date was Tuesday, March 12, 2024, before market open.
Earnings Date | Mar 12, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Enfusion has 89.87 million shares outstanding. The number of shares has increased by 51.57% in one year.
Shares Outstanding | 89.87M |
Shares Change (YoY) | +51.57% |
Shares Change (QoQ) | -0.21% |
Owned by Insiders (%) | 8.53% |
Owned by Institutions (%) | 95.62% |
Float | 39.60M |
Valuation Ratios
The trailing PE ratio is 132.14 and the forward PE ratio is 39.43.
PE Ratio | 132.14 |
Forward PE | 39.43 |
PS Ratio | 4.69 |
Forward PS | 3.92 |
PB Ratio | 15.24 |
P/FCF Ratio | 51.23 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 33.97, with an EV/FCF ratio of 49.97.
EV / Earnings | 132.39 |
EV / Sales | 4.57 |
EV / EBITDA | 33.97 |
EV / EBIT | 120.58 |
EV / FCF | 49.97 |
Financial Position
The company has a current ratio of 3.44, with a Debt / Equity ratio of 0.29.
Current Ratio | 3.44 |
Quick Ratio | 3.14 |
Debt / Equity | 0.29 |
Debt / EBITDA | 0.66 |
Debt / FCF | 0.97 |
Interest Coverage | -4.03 |
Financial Efficiency
Return on equity (ROE) is 11.10% and return on invested capital (ROIC) is 12.62%.
Return on Equity (ROE) | 11.10% |
Return on Assets (ROA) | 5.70% |
Return on Capital (ROIC) | 12.62% |
Revenue Per Employee | $158,380 |
Profits Per Employee | $5,467 |
Employee Count | 1,102 |
Asset Turnover | 1.64 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Enfusion has paid $2.23 million in taxes.
Income Tax | 2.23M |
Effective Tax Rate | 27.02% |
Stock Price Statistics
The stock price has decreased by -8.34% in the last 52 weeks. The beta is 0.99, so Enfusion's price volatility has been similar to the market average.
Beta (1Y) | 0.99 |
52-Week Price Change | -8.34% |
50-Day Moving Average | 8.75 |
200-Day Moving Average | 9.25 |
Relative Strength Index (RSI) | 56.86 |
Average Volume (30 Days) | 409,845 |
Short Selling Information
The latest short interest is 1.67 million, so 1.86% of the outstanding shares have been sold short.
Short Interest | 1.67M |
Short Previous Month | 1.70M |
Short % of Shares Out | 1.86% |
Short % of Float | 4.22% |
Short Ratio (days to cover) | 4.59 |
Income Statement
In the last 12 months, Enfusion had revenue of $174.54 million and earned $6.03 million in profits. Earnings per share was $0.07.
Revenue | 174.54M |
Gross Profit | 116.89M |
Operating Income | 11.95M |
Pretax Income | 8.26M |
Net Income | 6.03M |
EBITDA | 23.48M |
EBIT | 6.62M |
Earnings Per Share (EPS) | $0.07 |
Balance Sheet
The company has $35.60 million in cash and $15.44 million in debt, giving a net cash position of $20.17 million or $0.22 per share.
Cash & Cash Equivalents | 35.60M |
Total Debt | 15.44M |
Net Cash | 20.17M |
Net Cash Per Share | $0.22 |
Equity / Book Value | 53.67M |
Book Value Per Share | 0.60 |
Working Capital | 49.54M |
Cash Flow
In the last 12 months, operating cash flow was $25.63 million and capital expenditures -$9.67 million, giving a free cash flow of $15.96 million.
Operating Cash Flow | 25.63M |
Capital Expenditures | -9.67M |
Free Cash Flow | 15.96M |
FCF Per Share | $0.18 |
Margins
Gross margin is 66.97%, with operating and profit margins of 6.85% and 3.45%.
Gross Margin | 66.97% |
Operating Margin | 6.85% |
Pretax Margin | 4.73% |
Profit Margin | 3.45% |
EBITDA Margin | 13.46% |
EBIT Margin | 3.79% |
FCF Margin | 9.15% |
Dividends & Yields
Enfusion does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -51.57% |
Shareholder Yield | -51.57% |
Earnings Yield | 0.74% |
FCF Yield | 1.95% |
Analyst Forecast
The average price target for Enfusion is $9.33, which is 0.86% higher than the current price. The consensus rating is "Sell".
Price Target | $9.33 |
Price Target Difference | 0.86% |
Analyst Consensus | Sell |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Enfusion has an Altman Z-Score of 15.71 and a Piotroski F-Score of 5.
Altman Z-Score | 15.71 |
Piotroski F-Score | 5 |